Feasibility and efficacy demonstrated by scientific studies

Stem cell therapy for premature ovarian failure feasibility and efficacy were supported by scientific evidence.

In a recent study stem cell treatment of premature ovarian failure resumed menstruations and allowed a woman to get pregnant and to give birth to a full-term healthy baby.

Menstruations restarted 3 months after stem cell therapy in 20% of treated women, which regained ovarian reserve and the secretory function of a previously atrophic endometrium.


In another study, 60% of patient with idiopathic premature ovarian failure receiving autologous stem cell transplantation started ovulating. The same study find out an increase in anti-mullerian hormone levels in almost 90% of treated women only 1 month after stem cell therapy.

Finally, preliminary results of the ROSE (Rejuvenation of Premature Ovarian Failure With Stem Cells) clinical trial demonstrated that in 2 women who completed autologous bone marrow stem cell therapy serum estrogen levels already increased 3 months after stem cells injection. The effect lasted for at least 1 year, menopausal symptoms were alleviated, and menstruations resumed 6 months after the injection.